Summary of information on human CYP enzymes: human P450 metabolism data.
Article Details
- CitationCopy to clipboard
Rendic S
Summary of information on human CYP enzymes: human P450 metabolism data.
Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
- PubMed ID
- 11996015 [ View in PubMed]
- Abstract
This chapter is an update of the data on substrates, reactions, inducers, and inhibitors of human CYP enzymes published previously by Rendic and DiCarlo (1), now covering selection of the literature through 2001 in the reference section. The data are presented in a tabular form (Table 1) to provide a framework for predicting and interpreting the new P450 metabolic data. The data are formatted in an Excel format as most suitable for off-line searching and management of the Web-database. The data are presented as stated by the author(s) and in the case when several references are cited the data are presented according to the latest published information. The searchable database is available either as an Excel file (for information contact the author), or as a Web-searchable database (Human P450 Metabolism Database, www.gentest.com) enabling the readers easy and quick approach to the latest updates on human CYP metabolic reactions.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
- Drug Reactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
Drugs Interaction Integrate drug-drug
interactions in your softwareAbrocitinibBosentan The metabolism of Abrocitinib can be increased when combined with Bosentan. AbrocitinibPeginterferon alfa-2b The metabolism of Abrocitinib can be increased when combined with Peginterferon alfa-2b. AbrocitinibWarfarin The metabolism of Abrocitinib can be increased when combined with Warfarin. AbrocitinibDelafloxacin The metabolism of Abrocitinib can be increased when combined with Delafloxacin. AbrocitinibValsartan The metabolism of Abrocitinib can be decreased when combined with Valsartan.
